See more : ME Renewable Power Corporation (MEPW) Income Statement Analysis – Financial Results
Complete financial analysis of Isodiol International Inc. (ISOLF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Isodiol International Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Antelope Enterprise Holdings Limited (AEHL) Income Statement Analysis – Financial Results
- Career Design Center Co., Ltd. (CAEEF) Income Statement Analysis – Financial Results
- Morn Sun Feed Mill Corp. (1240.TWO) Income Statement Analysis – Financial Results
- Establishment Labs Holdings Inc. (ESTA) Income Statement Analysis – Financial Results
- Investment & Precision Castings Limited (INVPRECQ.BO) Income Statement Analysis – Financial Results
Isodiol International Inc. (ISOLF)
About Isodiol International Inc.
Isodiol International Inc. engages in the development, marketing, distribution, and sale of hemp-based consumer packaged goods and solutions in Canada and the United States. It develops and manufactures phytoceutical consumer products using pharmaceutical and nutraceutical grade phytochemical compounds. The company offers pharmaceutical grade cannabinoid crystalline isolates derived from exempt parts of the hemp plant, as well as micro-encapsulations and nanotechnology for consumable and topical skin care products. It is also involved in manufacturing and distributing hemp oil and nicotine e-liquids, as well as personal care products; provision of apparel and merchandising solutions; manufactures and sells hemp infused beverages; and supplies pharmaceutical products. The company is headquartered in Vancouver, Canada.
| Metric | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|
| Revenue | 16.65M | 14.84M | 266.91K | 12.98K |
| Cost of Revenue | 20.71M | 16.74M | 171.89K | 4.95K |
| Gross Profit | -4.05M | -1.90M | 95.01K | 8.02K |
| Gross Profit Ratio | -24.35% | -12.80% | 35.60% | 61.83% |
| Research & Development | 80.50K | 467.38K | 102.89K | 0.00 |
| General & Administrative | 16.56M | 11.89M | 1.84M | 0.00 |
| Selling & Marketing | 3.72M | 2.69M | 27.43K | 0.00 |
| SG&A | 25.09M | 15.71M | 2.68M | 1.92M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 25.17M | 16.18M | 2.68M | 1.92M |
| Cost & Expenses | 45.88M | 32.92M | 2.86M | 1.93M |
| Interest Income | -0.13 | 1.71K | 53.82K | 0.00 |
| Interest Expense | 4.47M | 2.21K | 71.57K | 57.56K |
| Depreciation & Amortization | 1.54M | 858.16K | 16.76K | 0.00 |
| EBITDA | -84.50M | -26.85M | -2.59M | -6.65M |
| EBITDA Ratio | -507.37% | -116.00% | -970.06% | -14,751.95% |
| Operating Income | -29.23M | -18.08M | -2.59M | -1.91M |
| Operating Income Ratio | -175.52% | -121.79% | -970.06% | -14,751.95% |
| Total Other Income/Expenses | -61.28M | -9.64M | -624.80K | -4.79M |
| Income Before Tax | -90.51M | -27.71M | -3.21M | -6.71M |
| Income Before Tax Ratio | -543.48% | -186.70% | -1,204.15% | -51,697.63% |
| Income Tax Expense | -225.38K | 226.86K | -16.76K | 0.00 |
| Net Income | -90.28M | -27.94M | -3.21M | -6.71M |
| Net Income Ratio | -542.13% | -188.22% | -1,204.15% | -51,697.63% |
| EPS | -2.35 | -1.33 | -1.01 | -4.53 |
| EPS Diluted | -2.35 | -1.33 | -1.01 | -4.53 |
| Weighted Avg Shares Out | 38.40M | 20.94M | 3.18M | 1.48M |
| Weighted Avg Shares Out (Dil) | 38.40M | 20.94M | 3.18M | 1.48M |
Source: https://incomestatements.info
Category: Stock Reports